Strategies To Accelerate Development And De-Risk Gene Therapy Manufacturing

With its potential to treat a broader set of indications, the number of gene therapies under development is increasing. Concurrently, the need for accelerated and de-risked pathways to manufacturing is vital to delivering these critical therapies to patients. Having a robust process and analytical development (PAD) plan in place from the start is imperative, not only to drive the reduction of timelines, operation risks, and COGs but also to enhance patient safety.

Working with an experienced PAD team, who has the expertise, know-how, and capabilities to guide you in developing robust processes and analytical methods is instrumental to the success of your gene therapy. Join viral vector PAD experts from MilliporeSigma as they showcase strategies for developing robust processes and analytics for efficient and de-risked manufacturing.